Last reviewed · How we verify
Auris-Sedina
Auris-Sedina is a sedative-hypnotic agent used to treat insomnia.
Auris-Sedina is a sedative-hypnotic agent used to treat insomnia. Used for Insomnia.
At a glance
| Generic name | Auris-Sedina |
|---|---|
| Sponsor | Laboratorios Osorio de Moraes Ltda. |
| Drug class | Benzodiazepine |
| Target | GABA_A receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
It works by enhancing the effects of the neurotransmitter gamma-aminobutyric acid (GABA) in the brain, leading to a calming effect and inducing sleep. This is achieved through its action on the GABA_A receptor, a ligand-gated chloride channel that plays a crucial role in regulating neuronal excitability.
Approved indications
- Insomnia
Common side effects
- Drowsiness
- Dizziness
- Headache
- Nausea
- Memory impairment
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Auris-Sedina CI brief — competitive landscape report
- Auris-Sedina updates RSS · CI watch RSS
- Laboratorios Osorio de Moraes Ltda. portfolio CI